Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Staar Surgical Co has the GF Score of 83, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Staar Surgical Co
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Staar Surgical Co (FRA:SR3) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Staar Surgical Co GF Score Related Terms
FRA:SR3 vs BLFS, ATRC, KMTS: GF Score Comparison
For the Medical Instruments & Supplies subindustry, Staar Surgical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staar Surgical Co GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's GF Score distribution charts can be found below:
* The bar in red indicates where Staar Surgical Co's GF Score falls into.
Staar Surgical Co (FRA:SR3) has a GF Score of 83 as of Jul. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Staar Surgical Co and its competitors. This is 14% above median its historical median of 73.00. Over the past decade, Staar Surgical Co's GF Score has ranged from 25.00 to 92.00.
Is Staar Surgical Co's GF Score too high?
Staar Surgical Co's current GF Score of 83 is 14% above median its 10-year median of 73.00. Over the past 10 years, this metric has ranged from a low of 25.00 to a high of 92.00. Overall, Staar Surgical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Staar Surgical Co's GF Score compare to BLFS and ATRC?
Staar Surgical Co's GF Score of 83 can be compared against companies in the Medical Devices & Instruments industry. Historically, Staar Surgical Co's own GF Score has ranged from 25.00 to 92.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Staar Surgical Co and its competitors. Staar Surgical Co's current GF Score is 83, which is 14% above median its own 10-year median of 73.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staar Surgical Co stock overvalued right now?
Based on GuruFocus' analysis, Staar Surgical Co (FRA:SR3) is currently considered Modestly Undervalued. The stock's GF Value™ is €26.74, compared to a current price of €23.78 — trading 11.1% below its estimated fair value. The current GF Score is 83, which is 14% above median its 10-year median of 73.00. Staar Surgical Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Staar Surgical Co (FRA:SR3), the current GF Score is 83 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staar Surgical Co (FRA:SR3) Overvalued in 2026?
Based on GuruFocus' analysis, Staar Surgical Co stock appears to be undervalued.
The current stock price of €23.78 is trading 11.1% below its estimated GF Value™ of €26.74.
GuruFocus considers Staar Surgical Co to be Modestly Undervalued.
Key valuation signals for FRA:SR3:
GF Score: 83 (14% above median its 10-year median of 73.00)
GF Value™: €26.74 vs. price of €23.78 (11.1% below fair value)
No single metric tells the full story. See the FRA:SR3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
83GF Score
Get the complete analysis for FRA:SR3
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SR3 has been successfully added to your 
